Study of Baseline Severity and One-Year Exacerbation Risk in Adults with Non-Cystic Fibrosis Bronchiectasis Using the BASE Framework

What this Trial Is About

Non-cystic fibrosis bronchiectasis NCFB is a chronic lung condition marked by permanent airway widening, poor mucus clearance, frequent infections, ongoing inflammation, and repeated flare-ups. Researchers are evaluating the Bronchiectasis Assessment of Severity and Exacerbations BASE framework to classify disease severity and predict the risk of flare-ups within 12 months using objective clinical and laboratory measures. The study is a prospective observational cohort aimed at developing and validating this new assessment tool for adults with NCFB. Participants will continue their usual medical care without any treatments assigned by the study. They will be divided into two groups a development cohort to create the BASE model, and a validation cohort to test the model without changes. Assessments include baseline clinical exams, lung function tests, chest imaging reviews, oxygen level measurements, and blood markers of inflammation. Follow-up will last for 12 months to track flare-ups, hospitalizations, lung function changes, inflammation levels, treatment changes, and clinical outcomes. During the study, participants will undergo regular evaluations and data collection to support the development and validation of the BASE framework. Researchers will measure the accuracy of the BASE model in classifying current disease severity and predicting future flare-up risk. Safety and health outcomes will be monitored throughout the year, with detailed data recorded at scheduled intervals. The studys goal is to provide a practical tool for managing NCFB severity and risk while patients receive their standard care.

BASE: Bronchiectasis Severity and Exacerbation Risk Study